YKL-40 and Complications in Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01387984|
Recruitment Status : Completed
First Posted : July 6, 2011
Last Update Posted : July 6, 2011
|Condition or disease|
|Type 2 Diabetes Mellitus|
It is well recognized now that diabetes mellitus is a systemic vasculopathy and causes various micro- and macrovascular complications. Vascular damage and endothelium dysfunction in diabetes mellitus involve a chronic inflammatory process via a complicated mechanism.
YKL-40 is a 40 kD lectin molecule. It is secreted by various cells, including macrophages, vascular smooth muscle cells and giant cells, and the level of YKL-40 is found elevated in both acute (eg. infection) and chronic (eg. rheumatoid arthritis, systemic lupus erythematosus or cirrhosis of the liver) inflammatory processes. The plasma concentration of YKL-40 is elevated in the patients of type 2 diabetes mellitus compared with non-diabetic controls, and is associated with insulin resistance, fasting plasma glucose and plasma IL-6 concentrations. Furthermore, the concentration of YKL-40 is elevated and is associated with the severity of albuminuria in the patients of type 1 diabetes.
The objective of this study is to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes, and to evaluate its potential as a biomarker for the vascular diabetic complications in patients with type 2 diabetes.
|Study Type :||Observational|
|Actual Enrollment :||473 participants|
|Official Title:||Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes|
|Study Start Date :||April 2010|
|Actual Primary Completion Date :||April 2010|
|Actual Study Completion Date :||April 2010|
|Type 2 diabetes mellitus|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01387984
|National Taiwan University Hospital Yun-Lin Branch|
|Douliu City, Yunlin County, Taiwan, 640|
|Principal Investigator:||Chih-Hung Lin, M.D.||National Taiwan University Hospital, Yun-Lin Branch|